RT @AdelaCastro222: The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active # | RheumNow

Register

Adela Castro @AdelaCastro222 Nov 12, 2022

The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims

Image from Adela Castro’s tweet

×